Ceapro Inc
XTSX:CZO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ceapro Inc
Cost of Revenue
Ceapro Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ceapro Inc
XTSX:CZO
|
Cost of Revenue
-CA$5.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-5%
|
|
|
Burcon NutraScience Corp
TSX:BU
|
Cost of Revenue
-CA$4.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
EcoSynthetix Inc
TSX:ECO
|
Cost of Revenue
-$14.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
5N Plus Inc
TSX:VNP
|
Cost of Revenue
-$273.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
2%
|
|
|
Nano One Materials Corp
TSX:NANO
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neo Performance Materials Inc
TSX:NEO
|
Cost of Revenue
-$345m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Ceapro Inc
Glance View
Ceapro, Inc. engages in the development and marketing of natural products for personal care, cosmetic, human, and animal health industries. The company is headquartered in Edmonton, Alberta. The firm's primary business activities relate to the development and marketing of various health and wellness products and technology relating to plant extracts. The firm operates through two segments: the active ingredient product technology industry and the cosmeceutical industry. The firm is engaged in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. The company supports the use of its extracts in cosmeceutical, nutraceutical and therapeutic products for humans and animals. Its pipeline Oat Beta Glucan and Avenanthramides. The Company’s wholly owned subsidiaries include Ceapro Technology Inc., Ceapro Active Ingredients Inc., Ceapro BioEnergy Inc., Ceapro (P.E.I) Inc., Ceapro USA Inc., and JuventeDC Inc.
See Also
What is Ceapro Inc's Cost of Revenue?
Cost of Revenue
-5.7m
CAD
Based on the financial report for Dec 31, 2023, Ceapro Inc's Cost of Revenue amounts to -5.7m CAD.
What is Ceapro Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-5%
Over the last year, the Cost of Revenue growth was 27%. The average annual Cost of Revenue growth rates for Ceapro Inc have been 9% over the past three years , -1% over the past five years , and -5% over the past ten years .
